📣 VC round data is live. Check it out!

Synmosa Biopharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Synmosa Biopharma and similar public comparables like Avacta Group, C4 Therapeutics, Medigen Vaccine Biologics, PKU Healthcare and more.

Synmosa Biopharma Overview

About Synmosa Biopharma

Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.


Founded

1970

HQ

Taiwan

Employees

473

Financials (FY)

Revenue: $197M
EBITDA: $38M

EV

$471M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Synmosa Biopharma Financials

Synmosa Biopharma reported last fiscal year revenue of $197M and EBITDA of $38M.

In the same fiscal year, Synmosa Biopharma generated $85M in gross profit, $38M in EBITDA, and $26M in net income.


Synmosa Biopharma P&L

In the most recent fiscal year, Synmosa Biopharma reported revenue of $197M and EBITDA of $38M.

Synmosa Biopharma is profitable as of last fiscal year, with gross margin of 43%, EBITDA margin of 19%, and net margin of 13%.

See analyst estimates for Synmosa Biopharma
Last FY202320242025202620272028
Revenue$197M$164M$177M$197M
Gross Profit$85M$67M$76M$85M
Gross Margin43%41%43%43%
EBITDA$38M$32M$34M$38M
EBITDA Margin19%20%19%19%
EBIT Margin13%12%13%13%
Net Profit$26M$19M$22M$26M
Net Margin13%12%12%13%
Net Debt$18M---

Financial data powered by Morningstar, Inc.

Synmosa Biopharma Stock Performance

Synmosa Biopharma has current market cap of $484M, and enterprise value of $471M.

Market Cap Evolution


Synmosa Biopharma's stock price is $0.96.

Synmosa Biopharma share price decreased by 0.2% in the last 30 days, and by 8.2% in the last year.

Synmosa Biopharma has an EPS (earnings per share) of $0.05.

See more trading valuation data for Synmosa Biopharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$471M$484M-0.2%-0.2%-2.0%-8.2%$0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Synmosa Biopharma Valuation Multiples

Synmosa Biopharma trades at 2.4x EV/Revenue multiple, and 12.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Synmosa Biopharma

Synmosa Biopharma Financial Valuation Multiples

As of June 2, 2026, Synmosa Biopharma has market cap of $484M and EV of $471M.

Synmosa Biopharma has a P/E ratio of 18.5x.

Last FY202320242025202620272028
EV/Revenue2.4x2.9x2.7x2.4x
EV/EBITDA12.3x14.7x14.0x12.3x
EV/EBIT19.0x23.8x20.0x19.0x
EV/Gross Profit5.5x7.0x6.2x5.5x
P/E18.5x25.6x22.2x18.5x
EV/FCF113.3x61.0x28.9x113.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Synmosa Biopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Synmosa Biopharma Margins & Growth Rates

In the most recent fiscal year, Synmosa Biopharma reported gross margin of 43%, EBITDA margin of 19%, and net margin of 13%.

See estimated margins and future growth rates for Synmosa Biopharma

Synmosa Biopharma Margins

Last FY20242025202720282029
Gross Margin43%43%43%
EBITDA Margin19%19%19%
EBIT Margin13%13%13%
Net Margin13%12%13%
FCF Margin2%9%2%

Synmosa Biopharma Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth8%12%
Gross Profit Growth13%12%
EBITDA Growth5%14%
EBIT Growth19%5%
Net Profit Growth15%20%
FCF Growth111%(74%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Synmosa Biopharma Operational KPIs

Synmosa Biopharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Synmosa Biopharma
Last FY202320242025202620272028
Revenue per Employee$0.4M---
Opex per Employee$0.1M---
S&M Expenses to Revenue16%17%18%16%
G&A Expenses to Revenue9%8%8%9%
R&D Expenses to Revenue6%4%5%6%
Opex to Revenue31%29%30%31%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Synmosa Biopharma Competitors

Synmosa Biopharma competitors include Avacta Group, C4 Therapeutics, Medigen Vaccine Biologics, PKU Healthcare, Luzhu Biotech, Ovid Therapeutics, Contineum Therapeutics, Autolus Therapeutics, CHO Pharma and CytoDyn.

Most Synmosa Biopharma public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Avacta Group3164.6x5472.1x(14.4x)(14.2x)
C4 Therapeutics8.5x10.1x(3.0x)-
Medigen Vaccine Biologics22.2x19.1x(111.9x)698.3x
PKU Healthcare1.6x-15.2x-
Luzhu Biotech-11.5x(21.8x)(1644.4x)
Ovid Therapeutics46.1x78.3x(7.9x)-
Contineum Therapeutics-87.2x(3.7x)(3.4x)
Autolus Therapeutics4.5x3.5x(1.4x)(1.4x)

This data is available for Pro users. Sign up to see all Synmosa Biopharma competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Synmosa Biopharma

When was Synmosa Biopharma founded?Synmosa Biopharma was founded in 1970.
Where is Synmosa Biopharma headquartered?Synmosa Biopharma is headquartered in Taiwan.
How many employees does Synmosa Biopharma have?As of today, Synmosa Biopharma has over 473 employees.
Is Synmosa Biopharma publicly listed?Yes, Synmosa Biopharma is a public company listed on Taipei Exchange.
What is the stock symbol of Synmosa Biopharma?Synmosa Biopharma trades under 4114 ticker.
When did Synmosa Biopharma go public?Synmosa Biopharma went public in 2003.
Who are competitors of Synmosa Biopharma?Synmosa Biopharma main competitors include Avacta Group, C4 Therapeutics, Medigen Vaccine Biologics, PKU Healthcare, Luzhu Biotech, Ovid Therapeutics, Contineum Therapeutics, Autolus Therapeutics, CHO Pharma, CytoDyn.
What is the current market cap of Synmosa Biopharma?Synmosa Biopharma's current market cap is $484M.
What is the current revenue of Synmosa Biopharma?Synmosa Biopharma's last fiscal year revenue is $197M.
What is the current EV/Revenue multiple of Synmosa Biopharma?Current revenue multiple of Synmosa Biopharma is 2.4x.
Is Synmosa Biopharma profitable?No, Synmosa Biopharma is not profitable.
How many companies Synmosa Biopharma has acquired to date?Synmosa Biopharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Synmosa Biopharma has invested to date?Synmosa Biopharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Synmosa Biopharma

Lists including Synmosa Biopharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial